GlassScriptPhysician profile
Hyatt P Degreen, III
NPI 1235345596
$5,551.58
in general payments reported to CMS, 2019-2025
50 companies · $895 in 2025
The $895 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $300 · 2020: $267 · 2021: $442 · 2022: $242 · 2023: $860 · 2024: $2,546 · 2025: $895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,269 · Travel and Lodging: $998 · Gift: $33.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,268.90 |
| Travel and Lodging | $998.22 |
| Gift | $33.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Oncology Corporate, INC. | $1,433.32 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $409.31 | 2019-2025 | Opdivo, Opdualag |
| Novartis Pharmaceuticals Corporation | $290.17 | 2019-2025 | |
| Abbvie INC. | $278.71 | 2021-2025 | Venclexta |
| Daiichi Sankyo INC. | $263.79 | 2023-2025 | Enhertu, Datroway |
| Astrazeneca Pharmaceuticals LP | $263.22 | 2023-2025 | Calquence, Enhertu |
| Pfizer INC. | $202.54 | 2019-2025 | |
| Celgene Corporation | $179.83 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Servier Pharmaceuticals LLC | $159.26 | 2021 | |
| Astellas Pharma US INC | $144.20 | 2019-2025 | Padcev, Vyloy |
| Merck Sharp & Dohme LLC | $133.33 | 2019-2024 | Keytruda, Lynparza |
| Seagen INC. | $116.98 | 2019-2023 | Adcetris, Tukysa |
| Beone Medicines USA, INC. | $101.42 | 2025 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $99.08 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $98.92 | 2019-2025 | Alunbrig, Iclusig, Fruzaqla |
Show all 48 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hyatt Degreen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.